|
|
|
|
Science Sparks @ ACTREC
|
 22 December 2025 |
Vol. No. 14 ; Issue No.714 |
|
|
Publications
|
|
1. Bhandari N, Devi YG, Acharya D, Bhat V, Chatterjee A, Yalshetti S, Arandkar S, Chaube BK, Shukla S (2025). MRPL47 deficiency drives mitochondrial dysfunction via ROS-p38-p21 signaling in non-small cell lung cancer.Journal of Biological Chemistry.
2. George A, Nair S, Prabhash K, Thakur S, Gera P, Singh A, Chaturvedi P, Rane S, Pradhan T, Sen S, Barkume M, Shetty D, Chaubal K, Ghosh A, Kamte S, Kode J (2026). Generation and characterization of early stage oral cancer cell line of buccal mucosa of Indian origin. Human Cell. 39: 21.
3. Joshi P, Kole L, Bavaskar M, Singh A, Shetty R, Nair S, Chaturvedi P (2025). Predictors of early versus late recurrence in post-surgical oral cancer patients. Journal of Surgical Oncology.
4. Mande R, Prasad M, Gala R, Parambil BC, Mohan R, Rane P, Chinnaswamy G (2025). Nutritional status and paediatric anthracycline early cardiotoxicity. BMJ Supportive and Palliative Care.
5. Panigrahi GC, Joshi A, Malhotra D, Gota V (2025). Mitocurcumin induces ROS-/JNK-mediated paraptosis to overcome chemoresistance in non-small cell lung cancer. Naunyn-Schmiedeberg's Archives of Pharmacology.
6. Bhat M, Narasimhan M, Shelar A, Patwardhan R, Sandur SK, Govekar R (2025). p38 MAPK-mediated suppression of Nrf2-MPC2 axis drives metabolic reprogramming which confers imatinib resistance in blast crisis phase of chronic myeloid leukemia. Experimental Cell Research.
|
|
|
|
|
Interesting Reads
|
|
Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, Mina R, Caeiro G, Kentos A, Hungria V, Reece D, Niu T, Mylin AK, Hansen CT, Teipel R, Besemer B, Dimopoulos MA, Zamagni E, Yoshihara S, Kim K, Min CK, Geerts P, Van Leeuwen-Segarceanu E, Tyczynska A, Reguera JL, Johansson M, Hansson M, Turgut M, Grey M, Sidana S, Rodriguez-Otero P, Martinez-Lopez J, Hashmi H, Carson R, Kobos R, Sun W, Lantz K, Seifert A, Briseno-Toomey D, O'Rourke L, Rubin M, Vieyra D, Kang L, Mateos MV (2025) MajesTEC-3 Trial Investigators. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine.
|
|
|
Video of the Week
|
|
| Precision Nanomedicine for Cancer: Importance of illuminating disease biology in vivo |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 1998, Dennis Salmon, showed that the drug Herceptin-r improves survival of women with advanced breast cancer.
|
|
|
|
|
|
2025 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
